Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jankovic, J.
Right arrow Articles by Frost, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jankovic, J.
Right arrow Articles by Frost, J. D., Jr.
NEUROLOGY 1984;34:688
© 1984 American Academy of Neurology

Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome

Joseph Jankovic, MD, Daniel G. Glaze, MD and James D. Frost, Jr., MD

From the Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston.

Supersensitivity of dopaminergic receptors may be responsible for the tics of Tourette's syndrome. Symptoms improve after treatment with dopamine blockers, but side effects limit use of these drugs. We evaluated tetrabenazine (which has both presynaptic monoaminedepleting effects and postsynaptic blocking action) in nine patients. Marked and lasting (more than 6 months) improvement occurred in four patients (ages 10 to 14 years), mild or transient (less than 6 months) improvement occurred in three patients (ages 11 to 20 years), and to patients (age 48 years) had minimal or no response. Side effects included drowsiness in six, "nervousness" in two, depression in two, parkinsonism in one, and oculogyric crises in one, but all undesirable effects cleared with maintenance or reduction of the dosage.

Address correspondence and reprint requests to Dr. Jankovic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030.

Presented at the thirty-fifth Annual Meeting of the American Academy of Neurology, San Diego, CA, April 29, 1983.

Accepted for publication September 6, 1983.




This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
B. S. Peterson, P. Thomas, M. J. Kane, L. Scahill, H. Zhang, R. Bronen, R. A. King, J. F. Leckman, and L. Staib
Basal Ganglia Volumes in Patients With Gilles de la Tourette Syndrome
Arch Gen Psychiatry, April 1, 2003; 60(4): 415 - 424.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. M. Robertson
Tourette syndrome, associated conditions and the complexities of treatment
Brain, March 1, 2000; 123(3): 425 - 462.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
W. G. Ondo, P. A. Hanna, and J. Jankovic
Tetrabenazine Treatment for Tardive Dyskinesia: Assessment by Randomized Videotape Protocol
Am J Psychiatry, August 1, 1999; 156(8): 1279 - 1281.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
J. Jankovic
Deprenyl in Attention Deficit Associated With Tourette's Syndrome
Arch Neurol, March 1, 1993; 50(3): 286 - 288.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. Gelernter, A. J. Pakstis, D. L. Pauls, R. Kurlan, S. T. Gancher, O. Civelli, D. Grandy, and K. K. Kidd
Gilles de la Tourette Syndrome Is Not Linked to D2-Dopamine Receptor
Arch Gen Psychiatry, November 1, 1990; 47(11): 1073 - 1077.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by AAN Enterprises, Inc.